Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GamEvac-Combi Immunogenicity and Safety in Ebola
NCT03072030Phase 4Completed
- Start
- Aug 2017
- Primary completion
- Dec 2019
- Modality
- Viral Vector Vaccines
- Countries
- 2
01
Overview
A Phase 4 trial of GamEvac-Combi in Ebola virus disease (EVD). Started Aug 2017; status: completed.
02
Drugs
GamEvac-Combi
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on NCT03072030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03072030.